These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23828945)

  • 1. The impact of local guidelines on the tumour marker requesting patterns of a General Surgery Department.
    Schulenburg-Brand D; Kumar N; Zouwail S
    Ann Clin Biochem; 2013 Sep; 50(Pt 5):438-42. PubMed ID: 23828945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An audit of tumour marker utilization in Greece.
    Ntaios G; Hatzitolios A; Chatzinikolaou A; Karalazou P; Savopoulos C; Karamouzis M; Pidonia I
    Eur J Intern Med; 2009 May; 20(3):e66-9. PubMed ID: 19393482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital.
    Loi S; Haydon AM; Shapiro J; Schwarz MA; Schneider HG
    Intern Med J; 2004; 34(9-10):545-50. PubMed ID: 15482267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An audit of tumour marker requests in Northern Ireland.
    McDonnell M;
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):378-84. PubMed ID: 15333189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour marker requesting in primary care and the role of the laboratory.
    Walker PL; Crook M
    J Clin Pathol; 2011 May; 64(5):443-6. PubMed ID: 21270062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor marker workshops.
    Rye PD; Nustad K; Stigbrand T
    Tumour Biol; 2003; 24(4):165-71. PubMed ID: 14654709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of alpha-fetoprotein, carcinoembryonic antigen and human chorionic gonadotropin producing renal cell carcinoma].
    Takakura N; Mimura H; Hamazaki K; Kim H; Hirata K; Miwata H; Kimura T; Sakata T; Hosoba T; Orita K
    Gan No Rinsho; 1987 Sep; 33(11):1385-90. PubMed ID: 2444728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality control in tumor marker values: methology, results and potential problems].
    Ben Ayed M; Ben Hadj Hmida Y; Kassis M; Damak J; Masmoudi H
    Tunis Med; 2001; 79(6-7):341-7. PubMed ID: 11771428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of tumour markers in nasopharyngeal carcinoma.
    Kuo WR; Tsai SM; Jong SB; Juan KH
    J Otolaryngol; 1996 Feb; 25(1):32-6. PubMed ID: 8816107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers and ovarian cancer].
    Trifonov I; Todorova M
    Akush Ginekol (Sofiia); 2002; 41 Suppl 1():7-11. PubMed ID: 12412346
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tumor markers for ovarian cancers].
    Aoki D; Kataoka F; Susumu N; Nozawa S
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():496-502. PubMed ID: 15535295
    [No Abstract]   [Full Text] [Related]  

  • 13. CA 125, CA 15.3, CA 27.29, CEA, beta-hCG and alpha-fetoprotein levels in cyst fluid of breast macrocysts.
    Martínez L; Castilla JA; Blanco N; Perán F; Herruzo A
    Int J Gynaecol Obstet; 1995 Feb; 48(2):187-92. PubMed ID: 7540567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
    Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
    Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sense and nonsense of tumor markers in practice].
    Joss R; Cerny T
    Schweiz Med Wochenschr; 1990 May; 120(19):693-703. PubMed ID: 1693445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practice in primary care pathology: review 13.
    Cabrera-Abreu JC; Smellie WS; Bowley R; Shaw N
    J Clin Pathol; 2012 Feb; 65(2):97-100. PubMed ID: 22039279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of cardiopulmonary resuscitation on levels of tumour markers.
    Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
    Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the test methods (KRYPTOR, ES 600 and CIS-RIA) for CEA, CA 15-3 and CA 125 follow-up and ONCOCHECK-quality control.
    Bauer T; Charl S; Sturm G
    Anticancer Res; 2000; 20(6D):5245-7. PubMed ID: 11326703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour markers: their use and misuse by clinicians.
    McGinley PJ; Kilpatrick ES
    Ann Clin Biochem; 2003 Nov; 40(Pt 6):643-7. PubMed ID: 14629802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
    Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
    Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.